Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 1.56
REGN's Cash to Debt is ranked lower than
74% of the 860 Companies
in the Global Biotechnology industry.

( Industry Median: 61.94 vs. REGN: 1.56 )
Ranked among companies with meaningful Cash to Debt only.
REGN' s 10-Year Cash to Debt Range
Min: 0.57  Med: 1.93 Max: No Debt
Current: 1.56
Equity to Asset 0.74
REGN's Equity to Asset is ranked higher than
58% of the 617 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. REGN: 0.74 )
Ranked among companies with meaningful Equity to Asset only.
REGN' s 10-Year Equity to Asset Range
Min: 0.18  Med: 0.55 Max: 0.93
Current: 0.74
0.18
0.93
Interest Coverage 22.43
REGN's Interest Coverage is ranked lower than
88% of the 381 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. REGN: 22.43 )
Ranked among companies with meaningful Interest Coverage only.
REGN' s 10-Year Interest Coverage Range
Min: 0.46  Med: 10.33 Max: 22.43
Current: 22.43
0.46
22.43
F-Score: 4
Z-Score: 30.19
M-Score: -2.00
WACC vs ROIC
9.93%
20.24%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) 31.17
REGN's Operating margin (%) is ranked higher than
92% of the 677 Companies
in the Global Biotechnology industry.

( Industry Median: -71.14 vs. REGN: 31.17 )
Ranked among companies with meaningful Operating margin (%) only.
REGN' s 10-Year Operating margin (%) Range
Min: -554.63  Med: -39.41 Max: 187.97
Current: 31.17
-554.63
187.97
Net-margin (%) 13.56
REGN's Net-margin (%) is ranked higher than
83% of the 677 Companies
in the Global Biotechnology industry.

( Industry Median: -67.10 vs. REGN: 13.56 )
Ranked among companies with meaningful Net-margin (%) only.
REGN' s 10-Year Net-margin (%) Range
Min: -565.66  Med: -46.43 Max: 54.43
Current: 13.56
-565.66
54.43
ROE (%) 16.72
REGN's ROE (%) is ranked higher than
88% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: -30.76 vs. REGN: 16.72 )
Ranked among companies with meaningful ROE (%) only.
REGN' s 10-Year ROE (%) Range
Min: -75.77  Med: -19.19 Max: 86.68
Current: 16.72
-75.77
86.68
ROA (%) 11.63
REGN's ROA (%) is ranked higher than
90% of the 866 Companies
in the Global Biotechnology industry.

( Industry Median: -27.09 vs. REGN: 11.63 )
Ranked among companies with meaningful ROA (%) only.
REGN' s 10-Year ROA (%) Range
Min: -28.05  Med: -13.45 Max: 44.08
Current: 11.63
-28.05
44.08
ROC (Joel Greenblatt) (%) 56.02
REGN's ROC (Joel Greenblatt) (%) is ranked higher than
90% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: -390.34 vs. REGN: 56.02 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
REGN' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -214.91  Med: -35.50 Max: 168.03
Current: 56.02
-214.91
168.03
Revenue Growth (3Y)(%) 71.60
REGN's Revenue Growth (3Y)(%) is ranked higher than
95% of the 412 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. REGN: 71.60 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
REGN' s 10-Year Revenue Growth (3Y)(%) Range
Min: -25.3  Med: 22.00 Max: 81.3
Current: 71.6
-25.3
81.3
» REGN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2014

REGN Guru Trades in Q3 2014

Paul Tudor Jones 2,499 sh (New)
Ken Fisher 583 sh (New)
Jim Simons 26,562 sh (+828.09%)
Steven Cohen 23,600 sh (+62.76%)
Joel Greenblatt 1,410 sh (+60.05%)
Frank Sands 4,967,466 sh (+1.22%)
Vanguard Health Care Fund 2,795,500 sh (unchged)
Ron Baron 7,109 sh (unchged)
Mario Gabelli 2,190 sh (-4.58%)
Andreas Halvorsen 1,080,682 sh (-63.53%)
Ray Dalio 1,600 sh (-91.30%)
» More
Q4 2014

REGN Guru Trades in Q4 2014

Ray Dalio 11,800 sh (+637.50%)
Ron Baron 7,490 sh (+5.36%)
Vanguard Health Care Fund 2,921,000 sh (+4.49%)
Frank Sands 4,986,177 sh (+0.38%)
Frank Sands 4,986,177 sh (+0.38%)
Mario Gabelli 2,190 sh (unchged)
Andreas Halvorsen Sold Out
Joel Greenblatt Sold Out
Steven Cohen Sold Out
Paul Tudor Jones Sold Out
Jim Simons Sold Out
Ken Fisher 524 sh (-10.12%)
» More
Q1 2015

REGN Guru Trades in Q1 2015

Jim Simons 167,488 sh (New)
Pioneer Investments 482 sh (New)
Ken Fisher 534 sh (+1.91%)
Frank Sands 5,010,161 sh (+0.48%)
Vanguard Health Care Fund 2,921,000 sh (unchged)
Mario Gabelli 2,190 sh (unchged)
Ron Baron 7,490 sh (unchged)
Ray Dalio Sold Out
» More
Q2 2015

REGN Guru Trades in Q2 2015

Paul Tudor Jones 400 sh (New)
Kyle Bass 2,506 sh (New)
Ray Dalio 800 sh (New)
Ken Fisher 565 sh (+5.81%)
Pioneer Investments Sold Out
Jim Simons Sold Out
Ron Baron 7,479 sh (-0.15%)
Mario Gabelli 2,145 sh (-2.05%)
Vanguard Health Care Fund 2,764,540 sh (-5.36%)
Frank Sands 4,218,968 sh (-15.79%)
» More
» Details

Insider Trades

Latest Guru Trades with REGN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 129.14
REGN's P/E(ttm) is ranked lower than
82% of the 220 Companies
in the Global Biotechnology industry.

( Industry Median: 33.70 vs. REGN: 129.14 )
Ranked among companies with meaningful P/E(ttm) only.
REGN' s 10-Year P/E(ttm) Range
Min: 9.83  Med: 75.84 Max: 161.8
Current: 129.14
9.83
161.8
Forward P/E 33.11
REGN's Forward P/E is ranked lower than
73% of the 164 Companies
in the Global Biotechnology industry.

( Industry Median: 23.42 vs. REGN: 33.11 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 134.20
REGN's PE(NRI) is ranked lower than
83% of the 216 Companies
in the Global Biotechnology industry.

( Industry Median: 33.30 vs. REGN: 134.20 )
Ranked among companies with meaningful PE(NRI) only.
REGN' s 10-Year PE(NRI) Range
Min: 10.65  Med: 77.23 Max: 162.62
Current: 134.2
10.65
162.62
P/B 16.09
REGN's P/B is ranked lower than
90% of the 747 Companies
in the Global Biotechnology industry.

( Industry Median: 4.11 vs. REGN: 16.09 )
Ranked among companies with meaningful P/B only.
REGN' s 10-Year P/B Range
Min: 1.43  Med: 7.89 Max: 26.42
Current: 16.09
1.43
26.42
P/S 17.46
REGN's P/S is ranked lower than
62% of the 604 Companies
in the Global Biotechnology industry.

( Industry Median: 10.47 vs. REGN: 17.46 )
Ranked among companies with meaningful P/S only.
REGN' s 10-Year P/S Range
Min: 2.06  Med: 11.98 Max: 27.97
Current: 17.46
2.06
27.97
POCF 117.62
REGN's POCF is ranked lower than
87% of the 202 Companies
in the Global Biotechnology industry.

( Industry Median: 32.50 vs. REGN: 117.62 )
Ranked among companies with meaningful POCF only.
REGN' s 10-Year POCF Range
Min: 7.52  Med: 56.23 Max: 359.87
Current: 117.62
7.52
359.87
EV-to-EBIT 52.15
REGN's EV-to-EBIT is ranked lower than
71% of the 235 Companies
in the Global Biotechnology industry.

( Industry Median: 26.88 vs. REGN: 52.15 )
Ranked among companies with meaningful EV-to-EBIT only.
REGN' s 10-Year EV-to-EBIT Range
Min: -106.3  Med: -6.85 Max: 2827.2
Current: 52.15
-106.3
2827.2
Shiller P/E 274.39
REGN's Shiller P/E is ranked lower than
88% of the 112 Companies
in the Global Biotechnology industry.

( Industry Median: 44.71 vs. REGN: 274.39 )
Ranked among companies with meaningful Shiller P/E only.
REGN' s 10-Year Shiller P/E Range
Min: 260.47  Med: 330.86 Max: 1446.63
Current: 274.39
260.47
1446.63
Current Ratio 3.80
REGN's Current Ratio is ranked lower than
54% of the 837 Companies
in the Global Biotechnology industry.

( Industry Median: 4.14 vs. REGN: 3.80 )
Ranked among companies with meaningful Current Ratio only.
REGN' s 10-Year Current Ratio Range
Min: 2.17  Med: 6.77 Max: 20.69
Current: 3.8
2.17
20.69
Quick Ratio 3.51
REGN's Quick Ratio is ranked lower than
54% of the 837 Companies
in the Global Biotechnology industry.

( Industry Median: 4.00 vs. REGN: 3.51 )
Ranked among companies with meaningful Quick Ratio only.
REGN' s 10-Year Quick Ratio Range
Min: 2.17  Med: 6.68 Max: 20.5
Current: 3.51
2.17
20.5
Days Inventory 168.44
REGN's Days Inventory is ranked lower than
65% of the 409 Companies
in the Global Biotechnology industry.

( Industry Median: 122.55 vs. REGN: 168.44 )
Ranked among companies with meaningful Days Inventory only.
REGN' s 10-Year Days Inventory Range
Min: 61.88  Med: 146.77 Max: 432.93
Current: 168.44
61.88
432.93
Days Sales Outstanding 115.17
REGN's Days Sales Outstanding is ranked lower than
76% of the 570 Companies
in the Global Biotechnology industry.

( Industry Median: 62.77 vs. REGN: 115.17 )
Ranked among companies with meaningful Days Sales Outstanding only.
REGN' s 10-Year Days Sales Outstanding Range
Min: 6.35  Med: 65.90 Max: 201.38
Current: 115.17
6.35
201.38

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 49.13
REGN's Price/Net Current Asset Value is ranked lower than
94% of the 540 Companies
in the Global Biotechnology industry.

( Industry Median: 6.84 vs. REGN: 49.13 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
REGN' s 10-Year Price/Net Current Asset Value Range
Min: 3.34  Med: 9.90 Max: 157.38
Current: 49.13
3.34
157.38
Price/Tangible Book 16.11
REGN's Price/Tangible Book is ranked lower than
85% of the 690 Companies
in the Global Biotechnology industry.

( Industry Median: 5.33 vs. REGN: 16.11 )
Ranked among companies with meaningful Price/Tangible Book only.
REGN' s 10-Year Price/Tangible Book Range
Min: 1.54  Med: 4.94 Max: 22
Current: 16.11
1.54
22
Price/Projected FCF 18.66
REGN's Price/Projected FCF is ranked lower than
83% of the 160 Companies
in the Global Biotechnology industry.

( Industry Median: 3.77 vs. REGN: 18.66 )
Ranked among companies with meaningful Price/Projected FCF only.
REGN' s 10-Year Price/Projected FCF Range
Min: 14.99  Med: 21.63 Max: 240.67
Current: 18.66
14.99
240.67
Price/Median PS Value 1.47
REGN's Price/Median PS Value is ranked lower than
68% of the 542 Companies
in the Global Biotechnology industry.

( Industry Median: 1.07 vs. REGN: 1.47 )
Ranked among companies with meaningful Price/Median PS Value only.
REGN' s 10-Year Price/Median PS Value Range
Min: 0.19  Med: 1.03 Max: 4.45
Current: 1.47
0.19
4.45
Price/Graham Number 9.14
REGN's Price/Graham Number is ranked lower than
87% of the 173 Companies
in the Global Biotechnology industry.

( Industry Median: 3.26 vs. REGN: 9.14 )
Ranked among companies with meaningful Price/Graham Number only.
REGN' s 10-Year Price/Graham Number Range
Min: 1.24  Med: 6.19 Max: 9.47
Current: 9.14
1.24
9.47
Earnings Yield (Greenblatt) (%) 1.97
REGN's Earnings Yield (Greenblatt) (%) is ranked higher than
80% of the 823 Companies
in the Global Biotechnology industry.

( Industry Median: -6.10 vs. REGN: 1.97 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
REGN' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 1.3  Med: 2.20 Max: 24.9
Current: 1.97
1.3
24.9

Analyst Estimate

Dec15 Dec16 Dec17 Dec18
Revenue(Mil) 4,039 4,875 5,830 6,732
EPS($) 10.27 15.00 19.54 25.08
EPS without NRI($) 10.27 15.00 19.54 25.08

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:0R2M.UK, REGN.Switzerland,
Regeneron Pharmaceuticals Inc was incorporated in in the State of New York on January 1988. The Company is a biopharmaceutical company that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. The Company's preclinical research programs are in the areas of oncology and angiogenesis, ophthalmology, metabolic and related diseases, muscle diseases and disorders, inflammation and immune diseases, bone and cartilage, pain, cardiovascular diseases, and infectious diseases. Its manufacturing facilities are located in Rensselaer, New York and consist of three buildings totaling approximately 490,000 square feet of research, manufacturing, office, and warehouse space. It currently has approximately 74,000liters of cell culture capacity at these facilities. It faces competition from pharmaceutical, biotechnology, and chemical companies. Its competitors are Genentech, Novartis, Pfizer Inc., Bayer HealthCare, Onyx Pharmaceuticals, Inc., Eli Lilly and Company, Abbott, sanofi-aventis, Merck & Co., Amgen Inc., Roche, and others. Its present and future business would be subject to regulation under the United States Atomic Energy Act, the Clean Air Act, the Clean Water Act, the Comprehensive Environmental Response, Compensation and Liability Act, the National Environmental Policy Act, the Toxic Substances Control Act, the Resource Conservation and Recovery Act, national restrictions, and other current and potential future local, state, federal, and foreign regulations.
» More Articles for REGN

Headlines

Articles On GuruFocus.com
Weekly CFO Sells Highlight: Acadia Healthcare, Facebook, Regeneron Pharmaceuticals Aug 24 2015 
Weekly Insider Sells Highlights: FB, AET, REGN, TYC Aug 18 2015 
Brean Capital Weighs in on Medivation Following Update on TERRAIN Study Mar 26 2015 
1 Feb 23 2015 
1 Feb 23 2015 
Can These Three BioTech Companies Make It Big? Feb 20 2015 
J.P. Morgan Chimes In With Ratings On BioTech Stocks Jan 06 2015 
Weekly Insider Sells Highlight: REGN, HSP, TYC, AAPL Nov 30 2014 
S&P 500 Finishes Above 2,000 Aug 27 2014 
How Sanofi's Growth Strategy Will Catapult Afrezza Into a Blockbuster Drug Aug 20 2014 

More From Other Websites
Cramer: Are high-reward biotech bargains worth it? Sep 02 2015
Cramer: What pushed this market higher? The sellers Sep 02 2015
Regeneron and Sanofi Present Encouraging Praluent Data Sep 02 2015
Regeneron Discovery on Cause of Rare Genetic Bone Disease Detailed in Science Translational Medicine... Sep 02 2015
Regeneron scientists discover key to excess bone growth in rare disease Sep 02 2015
4 Google-Beating Stocks that Still Hold Promise Sep 02 2015
Biotech: No, They Don't Look Like Bargains Sep 02 2015
The Zacks Analyst Blog Highlights: Amazon.com, Skyworks Solutions, Regeneron Pharmaceuticals and... Sep 02 2015
Intercept's (ICPT) OCA Under Priority Review in the U.S. Sep 01 2015
Netflix PT Hiked; CyberArk, American, Delta Upgraded Sep 01 2015
Gilead Sciences: Most Enticing Sep 01 2015
Avoid September's market pain in 9 ways Sep 01 2015
Regeneron and Sanofi Announce New Positive Praluent® (alirocumab) Phase 3 Data Presented at ESC... Sep 01 2015
Sanofi and Regeneron Announce New Positive Praluent® (alirocumab) Phase 3 Data Presented at ESC... Sep 01 2015
Stock Futures Take A Beating; Dollar Tree, Ambarella Slide Sep 01 2015
9:02 am Regeneron Pharms and Sanofi (ANY) announce new positive... Sep 01 2015
Regeneron and Sanofi Announce New Positive Praluent® (alirocumab) Phase 3 Data Presented at ESC... Sep 01 2015
Coverage initiated on Regeneron Pharms by Raymond James Sep 01 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK